Excessive gastric acid secretion is often caused by pathological reasons such as gastritis, gastric insufficiency, indigestion, etc. The gastric mucosal cells work abnormally, making it impossible to excrete excess gastric acid from the body. APIs commonly used in clinical practice to inhibit gastric acid secretion include Proton Pump Inhibitors (PPls), cholinergic drugs (Anticholinergic Drugs), and potassium competitive acid blockers (P-CAB).

Among them, PPls are the latest generation of acid-suppressing drugs currently in clinically, with powerful and long-lasting acid-suppressing effects. The proton pump acts on the last step in the gastric acid secretion process, after being absorbed into the bloodstream in the body, it reaches the secretory tubules of gastric parietal cells. It is converted into active substances in an acidic environment, acting on H+-K+-ATPase and inactivating it. As a result, hydrogen ions in parietal cells cannot be transferred to the gastric cavity, resulting in reduced gastric acid secretion, which in turn increases the pH value of gastric juice, thus achieving an acid-suppressive effect.

Protheragen-ING offers a full range of gastric acid secretion-inhibiting APIs to support the research of customers worldwide.